Navigation Links
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
Date:1/4/2008

paedic surgeries such as hip and knee replacement, bunionectomy, open fracture repair and certain bone graft procedures. Detailed market research performed independently by L.E.K. Consulting has predicted peak US sales of BUPIVACAINE SURGICAL IMPLANT nearing $310 million.

"This first dosing with our Bupivacaine Implant for the management of post-operative pain follows hot on the heels of other phase 2 and phase 3 trials recently initiated with our topically-applied Gentamicin-Collagen sponge for the treatment of infected diabetic foot ulcers and our Gentamicin Surgical Implant for the prevention of surgical site infection. This certainly marks a very exciting time for Innocoll as we embark upon the dosing of patients in three clinical trials for different products spanning three different therapeutic categories", said Dr. Michael Myers, Innocoll's President and CEO.

About Innocoll, Inc.

Innocoll is a privately held, specialty pharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. It develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R) and Liquicoll(R). Innocoll 's lead product, GENTAMICIN SURGICAL IMPLANT, for the treatment and prevention of surgical site infections, is approved for sale in 49 countries in Europe, Latin America, Middle East, Africa and Asia and is marketed under the following trade names; COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R) IMPLANT, GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R), GENTACOL(R), GENTACOLL(R), GARACOL(R), GARACOLL(R), and CRONOCOL(R). In 2005, Innocoll acquired the worldwide marketing rights for this product from Essex Chemis AG, an affiliated company of Schering-Plough Corporation (NYSE:

SOURCE Innocoll Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... and BOSTON , September 16, ... Chief Scientific Officer, Fiona Marshall , will give a ... G protein-coupled receptors using StaR ®   ... Advances in Drug Discovery and Development " virtual symposium run ... Chemical Society. The virtual symposium is on Wednesday, 24 September ...
(Date:9/15/2014)... , Sept. 16, 2014  Bayer HealthCare ... Espoo, Finland , have begun ... with ODM-201, an investigational oral androgen receptor inhibitor ... ODM-201 in men with castration-resistant prostate cancer who ... no detectable metastases. The trial is designed to ...
(Date:9/15/2014)... 15, 2014 GenomeDx Biosciences today announced ... American Society for Radiation Oncology (ASTRO) Annual Meeting ... Classifier, a genomic test capable of predicting aggressiveness ... improve patient outcomes for prostate cancer patients following ... recently published study that demonstrates how Decipher test ...
Breaking Medicine Technology:Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 3
... SILVER SPRING, Md., July 1, 2011 The ... Neohaler (indacaterol inhalation powder) for the long term, ... people with chronic obstructive pulmonary disease (COPD) including ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) COPD is a ...
... DUBLIN, July 1, 2011 ,   ... SHPGY ), the global specialty,biopharmaceutical company, announces that it ... District of New Jersey against each,of Amneal Pharmaceuticals, LLC ... Shire,s VYVANSE,patents. The lawsuits were initiated in ...
Cached Medicine Technology:FDA Approves Arcapta Neohaler to Treat Chronic Obstructive Pulmonary Disease 2Shire Files Lawsuits Against Sandoz and Amneal for Infringement of VYVANSE® (lisdexamfetamine dimesylate) Patents 2
(Date:9/16/2014)... September 16, 2014 A recent ... used as a dermal filler, “Expression”, which has not ... on the market to be used as an intra-nasal ... FDA for use as a dermal filler. Because of ... off-label for wrinkle reduction, and patients have had bad ...
(Date:9/16/2014)... September 16, 2014 Dr. Eric Millstein ... of ACLsurgeryLA.com , a specialty website devoted to ... As an avid sports lover and athlete, Dr. Millstein ... and recovery from injuries to maintain active, healthy lifestyles. ... patients a resource dedicated specifically to ACL injuries ...
(Date:9/16/2014)... OXNARD, CA (PRWEB) September 16, 2014 ... Jivraj, founder of the Anacapa Dental Art Institute in ... Spectrum Day Vancouver conference this weekend. , Dr. Jivraj, ... about All-on-4™ dental implants in his presentation ... he will deliver at 12:40 p.m. Saturday, Sept. 20, ...
(Date:9/16/2014)... 2014 MEDICC Review today ... genetics in Cuba. Although the articles do not ... are intrinsically connected, since cancers begin with errors in ... full spectrum of cancer control, from primary prevention to ... topic of an exclusive interview with National Medical ...
(Date:9/16/2014)... NY (PRWEB) September 16, 2014 Registration ... Run For The Warriors®, a 10K, 5K, and 1-mile ... The race is sponsored by Local 338 RWDSU/UFCW, the ... will begin at the Town of Babylon Town Hall ... http://www.hopeforthewarriors.org/2014LIRun . The run is organized by Hope ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Non-approved Dermal Filler 2Health News:FDA Warns Against Non-approved Dermal Filler 3Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 2Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 4Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 5Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 2Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 3Health News:The Hope For The Warriors Long Island Run For The Warriors to Honor Wounded and Families of the Fallen 2
... of,Public Welfare said today it is working with ... an abandoned child in,Lansdowne, Delaware County., An ... noon today and said, "I left a baby ... without providing any other information. Local law,enforcement was ...
... and large numbers of men, are interested in having cosmetic ... Journal of Plastic and Reconstructive Surgery. , ... in cosmetic surgery, liposuction or both, and another 23 percent ... Among men, 23 percent said they would be interested in ...
... /PRNewswire/ - The IND proposes a randomized Phase,III ... Best Supportive,Care (BSC) versus BSC alone for the ... gastroesophageal junction and stomach who,have failed adjuvant or ... of the IND and will direct the clinical ...
... Oct. 26 In a statewide,effort to help ... violence shelters, the Michigan State Medical Society (MSMS),Foundation ... and,distribute personal care items in conjunction with the ... Day" on,Saturday, October 27., "The women and ...
... WHEATON, Ill., Oct. 26 The following is a,media ... Rehabilitation Hospital is the 2007 recipient of the,James Brady ... or organization,that goes above and beyond to improve lives ... goals of the Brain Injury Association of,Illinois., In ...
... UniCare announced today a policy to,make it easy for ... the prescription drugs they need. A one-time override ... up so,that UniCare policyholders in the affected counties can ... in place for,members living in Los Angeles, Orange, San ...
Cached Medicine News:Health News:Safe Haven Hotline Receives Report of Abandoned Baby in Lansdowne 2Health News:Huge numbers willing to go under knife to alter their appearance, study finds 2Health News:Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract 2Health News:Michigan State Medical Society Foundation 'Makes A Difference' by Assisting Those in Crisis Shelters 2Health News:Marianjoy Rehabilitation Hospital to Receive James Brady Award From Brain Injury Association of Illinois 2Health News:UniCare Announces Temporary Pharmacy Guidelines for Customers Affected by the California Wildfires 2
... Carl Zeiss has successfully advanced into the ... success of this instrument is by no ... and stylish design. Maximum ergonomic convenience is ... be used with a surgical microscope, allowing ...
... superior tissue excision with precision-matched, diamond-honed tips. ... pattern to capture loose bodies drawn into ... pin buffering system to minimize tip breakage ... pin buffering system applies increasing tension to ...
Leg holder for arthroscopy....
Osteoprep instruments provide an array of bone shaping devices especially suited for notchplasties....
Medicine Products: